EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement

Emily Gill iD, Claire M Perks iD

International Journal of Molecular Sciences · 26.01.2024 · 25 (3) · 1557

DOI: 10.3390/ijms25031557 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.01.2024. Verfasst von Emily Gill und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Endocrinology Group, Learning & Research Building, Southmead Hospital, Translational Health Sciences, Bristol Medical School, Bristol BS10 5NB…. Hauptthemen laut MEDLINE: Quality of Life, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bristol.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder cancer is the tenth most common cancer and is a significant burden on health care services worldwide, as it is one of the most costly cancers to treat per patient. This expense is due to the extensive treatment and follow-ups that occur with costly and invasive procedures. Improvement in both treatment options and the quality of life these interventions offer has not progressed at the rates of other cancers, and new alternatives are desperately needed to ease the burden. A more modern approach needs to be taken, with urinary biomarkers being a positive step in making treatments more patient-friendly, but there is still a long way to go to make these widely available and of a comparable standard to the current treatment options. New targets to hit the major signalling pathways that are upregulated in bladder cancer, such as the PI3K/AkT/mTOR pathway, are urgently needed, with only one drug approved so far, Erdafitinib. Immune checkpoint inhibitors also hold promise, with both PD-1 and CDLA-4 antibody therapies approved for use. They effectively block ligand/receptor binding to block the immune checkpoint used by tumour cells. Other avenues must be explored, including drug repurposing and novel biomarkers, which have revolutionised this area in other cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeUrinary Bladder NeoplasmsHumansPhosphatidylinositol 3-KinasesCystectomyBiomarkersNeoplasm Invasiveness

Stichwörter der Autor:innen

biomarkersbladder cancer treatmentmuscle-invasive bladder cancernon-muscle-invasive bladder cancerradial cystectomytransurethral resection of the bladder tumour

Substanzen

Phosphatidylinositol 3-KinasesBiomarkers

Autor:innen und Institutionen

  • Cancer Endocrinology Group, Learning & Research Building, Southmead Hospital, Translational Health Sciences, Bristol Medical School, Bristol BS10 5NB, UK.

ORCID-Profile: Emily Gill, Claire M Perks

Förderung

  • University of Bristol

Zitieren

APA

Gill, E., & Perks, C. M. (2024). Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement. International Journal of Molecular Sciences, 25(3), 1557. https://doi.org/10.3390/ijms25031557

Vancouver

Gill E, Perks CM. Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement. International Journal of Molecular Sciences. 2024;25(3):1557. doi:10.3390/ijms25031557

BibTeX
@article{Gill2024,
  author = {Gill, Emily and Perks, Claire M},
  title = {Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {3},
  pages = {1557},
  doi = {10.3390/ijms25031557}
}
Kostenlos starten →